Cg Oncology, Common Stock Volatility Indicators Average True Range
| CGON Stock | 33.90 0.05 0.15% |
| Symbol |
The output start index for this execution was one with a total number of output elements of sixty. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of CG Oncology, Common volatility. High ATR values indicate high volatility, and low values indicate low volatility.
CG Oncology, Technical Analysis Modules
Most technical analysis of CG Oncology, help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for CGON from various momentum indicators to cycle indicators. When you analyze CGON charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About CG Oncology, Predictive Technical Analysis
Predictive technical analysis modules help investors to analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of CG Oncology, Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of CG Oncology, Common based on widely used predictive technical indicators. In general, we focus on analyzing CGON Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build CG Oncology,'s daily price indicators and compare them against related drivers, such as volatility indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of CG Oncology,'s intrinsic value. In addition to deriving basic predictive indicators for CG Oncology,, we also check how macroeconomic factors affect CG Oncology, price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
| 2010 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 0.0705 | 579.03 | 164.61 | 198.32 | PTB Ratio | 61.53 | 19.79 | 0.87 | 0.83 |
Be your own money manager
As an individual investor, you need to find a reliable way to track all your investment portfolios' performance accurately. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing you full analytical transparency into your positions, our tools can tell you how much better you can do without increasing your risk or reducing expected return.Generate Optimal Portfolios
Align your risk and return expectations
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CG Oncology, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.036 | Quarterly Revenue Growth 1.727 |
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.